Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] stock went on an upward path that rose over 11.65% on Friday, amounting to a one-week price decrease of less than -12.88%. The company report on February 19, 2021 that Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, announced that the underwriter of its previously announced underwritten public offering has exercised in full its option to purchase an additional 4,390,244 shares of its common stock at a price to the public of $1.025 per share, less underwriting discounts and commissions. After giving effect to the option closing, the aggregate gross proceeds to Diffusion from the offering were approximately $34.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Diffusion.
H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
Over the last 12 months, DFFN stock rose by 219.44%.
The market cap for the stock reached $104.70 million, with 64.01 million shares outstanding and 63.90 million shares in the current float. Compared to the average trading volume of 7.11M shares, DFFN stock reached a trading volume of 10198675 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Diffusion Pharmaceuticals Inc. [DFFN]:
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 21, 2018, representing the official price target for Diffusion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.19 The Price to Book ratio for the last quarter was 2.56, with the Price to Cash per share for the same quarter was set at 0.24.
DFFN Stock Performance Analysis:
Diffusion Pharmaceuticals Inc. [DFFN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.88. With this latest performance, DFFN shares dropped by -4.17% in over the last four-week period, additionally plugging by 11.65% over the last 6 months – not to mention a rise of 219.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 47.39, with the RSI for the last a single of trading hit 44.68, and the three-weeks RSI is set at 49.37 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 1.0909, while it was recorded at 1.1400 for the last single week of trading, and 0.9865 for the last 200 days.
Insight into Diffusion Pharmaceuticals Inc. Fundamentals:
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
DFFN Stock EPS
With the latest financial reports released by the company, Diffusion Pharmaceuticals Inc. posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DFFN.
Diffusion Pharmaceuticals Inc. [DFFN] Insider Position Details
There are presently around $6 million, or 6.60% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 2,832,739, which is approximately -5.214% of the company’s market cap and around 0.21% of the total institutional ownership; BLACKROCK INC., holding 830,471 shares of the stock with an approximate value of $0.95 million in DFFN stocks shares; and VANGUARD GROUP INC, currently with $0.45 million in DFFN stock with ownership of nearly 11.624% of the company’s market capitalization.
9 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 345,375 shares. Additionally, 13 investors decreased positions by around 527,392 shares, while 7 investors held positions by with 4,077,383 shares. The mentioned changes placed institutional holdings at 4,950,150 shares, according to the latest SEC report filing. DFFN stock had 5 new institutional investments in for a total of 267,889 shares, while 8 institutional investors sold positions of 342,505 shares during the same period.